company background image
MLSS

Milestone Scientific NYSEAM:MLSS Stock Report

Last Price

US$1.14

Market Cap

US$78.0m

7D

5.6%

1Y

-35.2%

Updated

10 Aug, 2022

Data

Company Financials +
MLSS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MLSS Stock Overview

Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally.

Milestone Scientific Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Milestone Scientific
Historical stock prices
Current Share PriceUS$1.14
52 Week HighUS$3.00
52 Week LowUS$0.75
Beta1.38
1 Month Change-5.79%
3 Month Change34.51%
1 Year Change-35.23%
3 Year Change102.06%
5 Year Change0.44%
Change since IPO-92.00%

Recent News & Updates

Shareholder Returns

MLSSUS Medical EquipmentUS Market
7D5.6%1.0%1.2%
1Y-35.2%-19.3%-11.6%

Return vs Industry: MLSS underperformed the US Medical Equipment industry which returned -21.4% over the past year.

Return vs Market: MLSS underperformed the US Market which returned -13.5% over the past year.

Price Volatility

Is MLSS's price volatile compared to industry and market?
MLSS volatility
MLSS Average Weekly Movement11.6%
Medical Equipment Industry Average Movement9.5%
Market Average Movement7.9%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: MLSS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: MLSS's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198926Arjan Haverhalshttps://www.milestonescientific.com

Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic.

Milestone Scientific Fundamentals Summary

How do Milestone Scientific's earnings and revenue compare to its market cap?
MLSS fundamental statistics
Market CapUS$78.01m
Earnings (TTM)-US$7.75m
Revenue (TTM)US$10.08m

7.7x

P/S Ratio

-10.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MLSS income statement (TTM)
RevenueUS$10.08m
Cost of RevenueUS$3.89m
Gross ProfitUS$6.19m
Other ExpensesUS$13.94m
Earnings-US$7.75m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.11
Gross Margin61.42%
Net Profit Margin-76.85%
Debt/Equity Ratio0%

How did MLSS perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is MLSS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MLSS?

Other financial metrics that can be useful for relative valuation.

MLSS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.5x
Enterprise Value/EBITDA-7.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does MLSS's PS Ratio compare to its peers?

MLSS PS Ratio vs Peers
The above table shows the PS ratio for MLSS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.2x
UTRS Minerva Surgical
1.3x24.7%US$67.8m
LNSR LENSAR
1.9x27.1%US$70.0m
RWLK ReWalk Robotics
11.7x37.2%US$64.5m
ELMD Electromed
2x11.7%US$79.6m
MLSS Milestone Scientific
7.7x18.7%US$78.0m

Price-To-Sales vs Peers: MLSS is expensive based on its Price-To-Sales Ratio (7.7x) compared to the peer average (4.2x).


Price to Earnings Ratio vs Industry

How does MLSS's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Sales vs Industry: MLSS is expensive based on its Price-To-Sales Ratio (7.7x) compared to the US Medical Equipment industry average (4.1x)


Price to Sales Ratio vs Fair Ratio

What is MLSS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MLSS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.7x
Fair PS Ratio3.1x

Price-To-Sales vs Fair Ratio: MLSS is expensive based on its Price-To-Sales Ratio (7.7x) compared to the estimated Fair Price-To-Sales Ratio (3.1x).


Share Price vs Fair Value

What is the Fair Price of MLSS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MLSS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MLSS's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Milestone Scientific forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


5.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MLSS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MLSS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MLSS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MLSS's revenue (18.7% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: MLSS's revenue (18.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MLSS's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Milestone Scientific performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-5.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MLSS is currently unprofitable.

Growing Profit Margin: MLSS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MLSS is unprofitable, and losses have increased over the past 5 years at a rate of 5.3% per year.

Accelerating Growth: Unable to compare MLSS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MLSS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2%).


Return on Equity

High ROE: MLSS has a negative Return on Equity (-52.89%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Milestone Scientific's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MLSS's short term assets ($18.2M) exceed its short term liabilities ($3.8M).

Long Term Liabilities: MLSS's short term assets ($18.2M) exceed its long term liabilities ($472.7K).


Debt to Equity History and Analysis

Debt Level: MLSS is debt free.

Reducing Debt: MLSS had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MLSS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MLSS has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 9.5% each year.


Discover healthy companies

Dividend

What is Milestone Scientific current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MLSS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MLSS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MLSS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MLSS's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MLSS has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Arjan Haverhals (60 yo)

1.92yrs

Tenure

US$735,024

Compensation

Mr. Jan Adriaan Haverhals, also known as Arjan, serves as Chief Executive Officer at Milestone Medical, Inc. since June 2021. He has been President of Milestone Scientific Inc. since September 2020 and has...


CEO Compensation Analysis

Compensation vs Market: Arjan's total compensation ($USD735.02K) is about average for companies of similar size in the US market ($USD770.24K).

Compensation vs Earnings: Arjan's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MLSS's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: MLSS's board of directors are considered experienced (8.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MLSS insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.


Top Shareholders

Company Information

Milestone Scientific Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Milestone Scientific Inc.
  • Ticker: MLSS
  • Exchange: NYSEAM
  • Founded: 1989
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$78.013m
  • Shares outstanding: 68.43m
  • Website: https://www.milestonescientific.com

Number of Employees


Location

  • Milestone Scientific Inc.
  • 425 Eagle Rock Avenue
  • Suite 403
  • Roseland
  • New Jersey
  • 7068
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/10 00:00
End of Day Share Price2022/08/10 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.